Introduction
Propoxyphene is a weak synthetic diphenyl heptane opioid analgesic, similar in structure to methadone, which is used in the treatment of mild to moderate pain (1). Propoxyphene's analgesic activity resides in the d-enantiomer, dextropropoxyphene (2) , which is both a m receptor agonist and an N-methyl-D-aspartate (NMDA) receptor antagonist (3) . Propoxyphene has an estimated average half-life of 13 hours in young adults and 35 hours in the elderly (4) , and is primarily metabolized by N-demethylation through the CYP3A4 enzyme to norpropoxyphene (2) . Norpropoxyphene has an extended half-life averaging 22 hours in young adults and 41 hours in the elderly (4) ; it is associated with cardiac toxicity (2) . Propoxyphene was marketed in individual formulations and in combinations with aspirin, acetaminophen and caffeine (5) . At the time of its withdrawal from the US market in November 2010, propoxyphene was available as a Schedule IV controlled substance in six single-entity products and 22 acetaminophen combination products, associated with brand names Darvon and Darvocet, respectively (6) .
Propoxyphene was first approved by the US Food and Drug Administration (FDA) in 1957 (6) and quickly gained popularity as a non-narcotic analgesic with similar efficacy to other opioids, with fewer side effects. After its addition to the US market, studies indicated that propoxyphene and its combinations with acetaminophen were no more effective than codeine, aspirin, ibuprofen or acetaminophen alone (7) (8) (9) . In the 1960s and 1970s, propoxyphene became associated with abuse, overdose and overdose-related deaths, primarily associated with concomitant alcohol or drug use, thus losing its non-controlled status in 1977 (10) . Cardiotoxic effects of propoxyphene such as hypotension, bradycardia, asystole, bundle branch block, wide QRS complexes and decreased contractility are thought to be unresponsive to the opioid antagonist naloxone (11) , and fatalities as a result of propoxyphene overdose may occur rapidly. According to a 1975 survey of deaths, 20% of deaths occurred within the first hour of ingestion and 5% occurred within 15 minutes (12) . A review of the Florida Medical Examiner's Office mortality data undertaken by the Office of Surveillance and Epidemiology/Division of Epidemiology (OSE/DEPI) provided an estimate of 16 propoxyphene-related deaths per 100,000 prescriptions during [2003] [2004] [2005] [2006] [2007] , which exceeded the rate of deaths for both tramadol and hydrocodone. These findings were consistent with an additional OSE review of the Drug Abuse Warning Network (DAWN) data from 2004 -2007(6) . Due to similar concerns, the UK initiated a phased withdrawal of co-proxamol ( propoxyphene/acetaminophen) from the beginning of 2005 until the end of 2007. A subsequent UK study of the co-proxamol withdrawal period revealed a significant decrease in the number of co-proxamol-associated suicides and deaths of undetermined intent within this time period (13) .
To address concerns over cardiotoxicity at therapeutic doses, Xanodyne Pharmaceuticals was required to perform a Thorough QT (TQT) study to determine propoxyphene effects on cardiac electrophysiology. Preliminary results from the TQT study revealed a significant QTc interval prolongation at daily doses of 600 and 900 mg of propoxyphene. Dose-dependent prolongation of PR and QRS intervals were also noted. That study, in combination with previous safety concerns, led to the voluntary withdrawal of propoxyphene from the US market in November of 2010 (6) .
If appropriate procedures were undertaken by hospitals, pharmacies and manufacturers for the removal of propoxyphene from the US, remaining supplies of propoxyphene should be limited to leftover patient medications and supplies acquired from foreign sources. Whether or not patients are still obtaining propoxyphene from these sources, thus supporting a need for continual monitoring of propoxyphene, is a common question amongst providers practicing in pain management. To the authors' knowledge, prevalence data concerning propoxyphene use has not been reported since its withdrawal from the US market. This study reviews propoxyphene prevalence in the urine of chronic pain patients during the year leading up to its withdrawal and reports recent prevalence data for the year following its withdrawal. These data may serve as a baseline for determining if continued testing for this drug is necessary in US populations.
Experimental
Subjects and specimens A total of 417,914 urine specimens were collected over the period of January 1, 2010, through December 31, 2011, from 630 clinics involved in pain management located in 24 states (Alabama, Arkansas, Delaware, Florida, Georgia, Illinois, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Missouri, Mississippi, North Carolina, Nebraska, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, Virginia and West Virginia). The specimens were tested by Aegis Sciences (Nashville, TN) for a range of prescribed and illicit drugs. Specimen validity testing was also performed, which included testing for creatinine, specific gravity, pH, nitrites and chromates. Specimens confirming positive for propoxyphene were assembled into a database containing only test results and demographic data. A specimen was considered positive for propoxyphene if the specimen was confirmed positive by liquid chromatography -tandem mass spectrometry (LC -MS-MS) analysis for propoxyphene and/or norpropoxyphene. No patient information was included. All specimen data were encoded with a study identifier to protect the patient's confidentiality. No medication history was available for interpretation of results. The protocol for this study was approved by the Essex Institutional Review Board.
LC -MS-MS analyses
All specimens were directly, simultaneously analyzed for propoxyphene and norpropoxyphene (without screening) by a previously published and validated LC -MS-MS procedure (14) . Propoxyphene and norpropoxyphene standards were purchased from Cerilliant Corporation (Round Rock, TX). Propoxyphene-d 5 and Norpropoxyphene-d 5 (Cerilliant Corporation) were used as the internal standards for both propoxyphene and norpropoxyphene, respectively.
During analysis, specimens were stored under refrigerated conditions. An aliquot (0.125 mL) of each specimen was treated with deuterated standards and prepared for LC-MS-MS confirmation analysis. LC separation was conducted on a Shimadzu LC-20AD using a C18 column with 10 mM ammonium acetate, 0.1% formic acid water and 0.1% formic acid acetonitrile. Identification and measurement of analytes was performed with an API 3200 tandem MS operating in positive electrospray mode (ESI) (MDS SCIEX, Toronto, ON, Canada). The optimum conditions were as follows: curtain gas (nitrogen), 30 psi; collision activated dissociation, 5 psi; heated nebulizer temperature, 6008C; gas 1 (nitrogen), 75 psi; and gas 2 (nitrogen), 65 psi. To establish the appropriate multiple reaction monitoring (MRM) conditions for individual compounds, solutions of standards in methanol-water (50:50, v/v) were infused into the MS, and the declustering potential (DP) and collision energy (CE) were optimized for the different transitions. Data acquisition, peak integration and calculation were performed by a computer workstation running Analyst 1.4.2 or Analyst 1.5.2 software. Selected ions monitored, precursor and product ions (m/z) for the analytes, limit of quantitation (LOQ), upper limit of quantitation (ULOQ), inter-assay precision and accuracy for propoxyphene and norpropoxyphene are listed in Table I .
General criteria for identification and measurement of the analytes were as follows: relative retention time (RRT) of each analyte in the specimen had to be within +0.01 of the RRT in the calibrator or the retention time of each analyte in the sample had to be within +3% of its respective RT in the calibrator; ion ratios for the product ions derived from analytes and internal standards in controls and donor specimens had to be within the +20% mean range of those obtained from the corresponding substances in the calibrator; control samples had to measure within +20% of the in-house determined mean value; and negative controls must not have analytes above the LOQ. All quantitative data for drugs and metabolites were included in this report that met identification and quantitation (!LOQ) criteria.
Results and Discussion
Propoxyphene was withdrawn from the US market on November 19, 2010. From January 1, 2010, until December 31, 2010, propoxyphene was positive in 5,516 out of 142,548 specimens tested (3.87% prevalence). As expected, a significant drop in propoxyphene positives was observed from November to December, 2010 (3.81% of total specimens in November, 2.35% in December), coinciding with the withdrawal of propoxyphene from the US market. During the year following propoxyphene withdrawal (2011), propoxyphene was positive in 1,623 specimens out of 275,366 specimens tested (0.59% prevalence). Since December 2010, a steady decline in the percentage of propoxyphene positives has been observed ( Figure 1 ). The lowest prevalence rate occurred in December 2011, with 69 propoxyphene positives out of 25,658 specimens tested (0.27% prevalence, one out of every 370 specimens). Propoxyphene prevalence, mean concentrations of propoxyphene and its metabolite and quartile concentrations sorted by time period are listed in Table II . Changes in concentrations over time were most notable with norpropoxyphene (Figure 2 ), which exhibited a stable decline in median concentrations months prior to propoxyphene's removal from the US market. A potential explanation for this decrease may be a shift from chronic use to infrequent use of propoxyphene in the pain management population. Considering norpropoxyphene's longer half-life in comparison to propoxyphene, norpropoxyphene concentrations are more likely to accumulate with chronic, consistent use; therefore, one would expect higher normetabolite concentrations in a population of chronic users versus infrequent users of a particular drug. Switching to less frequent propoxyphene use would likely have less effect on propoxyphene concentrations. The data in Table II (15) . Infrequent use would also be expected following propoxyphene withdrawal due to limited availability.
Given that propoxyphene can no longer be legally obtained in the US due to market withdrawal, sources of propoxyphene are likely to be the remains of previous prescriptions or pharmaceutical products illegally obtained from outside the US, such as internet drug sales. According to SDI's VONA data, over 14 million prescriptions for the combination product propoxyphene/acetaminophen were dispensed in 2010 (15); thus supporting the likelihood that a significant supply of propoxyphene containing medications is still remaining. In 2011, the National Association of Boards of Pharmacy (NABP) reported than an estimated 96% of internet drug outlets (8, 353 reviewed) were noncompliant with state and federal laws and/or NABP patient safety and pharmacy practice standards; 44% of reviewed sites offered foreign or non-FDA-approved drugs (16) . Although the internet is a potential source for access to withdrawn medications such as propoxyphene, the 2010 National Survey on Drug Use and Health (NSDUH) revealed that only 0.4% of persons using pain relievers for nonmedical purposes obtained their most recent supply from an internet source; the majority (71.2%) obtained them from a friend or relative. Other sources included prescription from one doctor (17.3%) and drug dealers/strangers (4.4%) (17) . The source from which the patients obtained propoxyphene is unable to be determined from this study; however, given the NSDUH survey findings, one might propose the source to be primarily leftover medications from the patient or friend/family members of the patient. Regardless, this study confirms that propoxyphene is still being used in a small subset of the pain management population, with its most recent prevalence rate of 0.27% comparable to meperidine prevalence (0.37%) during the same time period (methods published previously) (14) . These data may be beneficial to US urine drug testing programs determining the need for continual monitoring of propoxyphene levels. If propoxyphene prevalence continues to further decline, urine testing programs may choose to remove this analyte from their testing profiles. Number of positives includes the number of specimens with concentrations ! LOQ for propoxyphene and/or norpropoxyphene; percent positive was calculated as 100 Â (number of positives/number of total specimens tested for propoxyphene during the specified quarter). ‡ SEM: standard error of the mean. 
Conclusion
This study shows the declining positivity rate of propoxyphene and/or its normetabolite in urine specimens received from the pain management setting during the time period leading up to and following the withdrawal of propoxyphene from the US market. Prevalence data revealed a gradual trend of diminishing use, ending with one out of every 370 urine specimens reporting positive for propoxyphene and/or norpropoxyphene. The prevalence of propoxyphene should be reassessed in the upcoming year to determine whether there is a continual need to monitor for abuse of this drug in the pain management setting.
